We have obtained a predictive model for TNM which combines peripheral blood parameters (% CD27+ CD4+ lymphocytes, % IDO+ monocytes, LAG3 MFI in CD4+ lymphocytes) with histological grade and tumor size and discriminates pTa and pT1 tumors with a sensitivity of 75% and specificity of 96.65%. The gene discussed is CD4; the disease is neoplasm.